论文部分内容阅读
目的:探讨中药联合恩替卡韦治疗乙肝后肝硬化患者血清ALT、AST以及AST/ALT的变化。方法:2016年1月2017年1月间,选取80例我院乙肝肝硬化患者,随机分为观察组和对照组。其中观察组采用中药方剂联合恩替卡韦治疗,对照组患者采用恩替卡韦治疗。治疗6后,观察两组患者血清转氨酶(丙氨酸氨基转移酶和天冬氨酸转氨酶)以及AST/ALT的变化。结果:治疗6月后观察组患者ALT和AST分别为(118.35±21.17)U/L和(126.76±28.43)U/L,而对照组患者ALT和AST分别为(166.47±22.36)U/L和(198.36±30.31)U/L,比较差异有统计学意义(P<0.05)。两组患者ALT/AST的比较,差异无统计学意义(P>0.05)。结论:中西医结合治疗乙肝肝硬化患者,可以明显改善患者血清转氨酶指标,改善肝功能效果更加明显。
Objective: To investigate the changes of serum ALT, AST and AST / ALT in patients with posthepatitic cirrhosis treated with traditional Chinese medicine and entecavir. Methods: January 2016 January 2017, 80 cases of hepatitis B cirrhosis in our hospital were selected and randomly divided into observation group and control group. The observation group was treated with traditional Chinese medicine prescription and entecavir, and the control group was treated with entecavir. After treatment 6, the changes of serum transaminases (alanine aminotransferase and aspartate aminotransferase) and AST / ALT were observed in both groups. Results: After 6 months of treatment, ALT and AST in the observation group were (118.35 ± 21.17) U / L and (126.76 ± 28.43) U / L, respectively, while those in the control group were 166.47 ± 22.36 U / L and (198.36 ± 30.31) U / L, the difference was statistically significant (P <0.05). There was no significant difference in ALT / AST between two groups (P> 0.05). Conclusion: Integrative treatment of hepatitis B cirrhosis patients can significantly improve the serum transaminase index, improve liver function effect is more obvious.